This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Subscribe To Our Newsletter & Stay Updated
